Vizimpro (dacomitinib) vs Krazati (adagrasib)

Vizimpro (dacomitinib) and Krazati (adagrasib) are both oral medications used for the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. Vizimpro is a second-generation tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR) and is indicated for the first-line treatment of patients with NSCLC harboring EGFR exon 19 deletions or exon 21 L858R mutations. Krazati, on the other hand, is a KRAS G12C inhibitor indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy; it targets a different mutation and is used in a different treatment setting compared to Vizimpro. The choice between these two medications would depend on the specific genetic alterations present in the patient's tumor, as well as their previous treatments and overall health condition. It is important for patients to discuss with their healthcare provider to determine which medicine is appropriate for their particular case.

Difference between Vizimpro and Krazati

Metric	Vizimpro (dacomitinib)	Krazati (adagrasib)
Generic name	Dacomitinib	Adagrasib
Indications	First-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations	Investigational for treatment of patients with KRAS G12C-mutated NSCLC
Mechanism of action	Irreversible inhibitor of the epidermal growth factor receptor (EGFR) family	Covalent inhibitor of KRAS G12C mutation
Brand names	Vizimpro	Krazati
Administrative route	Oral	Oral
Side effects	Diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, pruritus	Currently under investigation; specific side effects in the context of clinical trials are not yet fully established
Contraindications	Patients with a history of severe hypersensitivity to dacomitinib or any other component of Vizimpro	Not fully established as the drug is investigational; however, generally contraindicated in patients with known hypersensitivity to adagrasib or any of its excipients
Drug class	Tyrosine kinase inhibitor	KRAS inhibitor
Manufacturer	Pfizer	Mirati Therapeutics

Efficacy

Vizimpro (dacomitinib) for Lung Cancer

Vizimpro (dacomitinib) is a kinase inhibitor specifically designed for the treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. The efficacy of Vizimpro was established in a randomized, multicenter, open-label, active-controlled trial (ARCHER 1050). Patients treated with Vizimpro showed a significant improvement in progression-free survival compared to those treated with gefitinib, another EGFR inhibitor. The median progression-free survival for patients receiving Vizimpro was notably longer, indicating its effectiveness in delaying disease progression in the specified patient population.

Krazati (adagrasib) for Lung Cancer

Krazati (adagrasib) is a newer medication that targets a specific subset of NSCLC. As of the knowledge cutoff date, Krazati is an investigational, orally bioavailable small molecule designed to inhibit KRAS G12C mutations. These mutations are present in a subset of NSCLC cases and are known to drive tumor growth. While Krazati is still under clinical investigation, early clinical trials have demonstrated promising anti-tumor activity in patients with NSCLC harboring the KRAS G12C mutation. The drug has shown a high degree of specificity for the mutant KRAS protein and has been associated with a reduction in tumor size in some patients.

Both Vizimpro and Krazati represent a shift towards precision medicine in the treatment of lung cancer, where therapies are tailored to target specific genetic alterations within tumors. The efficacy of these drugs is closely tied to the presence of particular mutations, emphasizing the importance of genetic testing in the management of NSCLC. As research progresses, these targeted therapies may offer new hope for patients with advanced lung cancer, providing more effective and personalized treatment options.

It is essential for healthcare providers to stay informed about the latest clinical trial results and the evolving landscape of lung cancer treatment to best serve their patients. As new data emerge, the efficacy profiles of medications like Vizimpro and Krazati may become clearer, potentially leading to their integration into standard treatment regimens for NSCLC with specific genetic alterations. Until then, ongoing clinical trials and research continue to be crucial in evaluating the full potential of these targeted therapies.

Regulatory Agency Approvals

Vizimpro

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Krazati

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Vizimpro or Krazati today

If Vizimpro or Krazati are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Vizimpro

Buy Krazati

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: